Related to China’s Biostar, FMMU Collaborate to Take Skin Disease Drug Through Trials for Military

• RuiYi Licenses mAb Development to China's Genor
  
• SciClone Bringing Zensun's Heart Failure Drug to China
  
• Collaboration Aims to Create In Vitro Human Skin
  
• Novo Acquires Anti-Infective Developer Xellia for $700M
  
• Achaogen Scores $26.6M Five-Year Contract Covering Biothreat Bacterial Strains
  
• Royal DSM Makes $110M Investment in NCPC and Creates Three Joint Ventures
  
• Northeast Biodefense Center Pockets $46M from the NIAID
  
• PerkinElmer Makes Two Acquisitions to Pad Diagnostics Business in Emerging Markets
  
• AVI BioPharma Obtains Expanded DoD Contract Worth $11.5M for Its Junin Virus Infection Treatment
  
• GC-Rise and JS Bio Pharm Sign Separate Agreements for MediGene’s Genital Warts Treatment
  
• Synedgen Wins $2.73M U.S. Army Grant to Combat Drug-Resistant Bacteria
  
• Trius Wins $29.5M Contract to Develop Antibiotics for Gram-Negative Pathogens
  
• Pulmatrix Gets $5.7M DARPA Funding To Develop Host-Targeted Inhaled Therapies
  
• DoD Pledges $4.6M to Establish Infection Genomics Center at UTSA
  
• GSK Awarded $38.5M Contract to Develop Antibiotic for Biodefense and Drug-Resistant Infections
  
• CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program
  
• Translational Medicine Center for Infectious Diseases Set Up in Shanghai
  
• Life Technologies, DaAn Establish Chinese Diagnostics Joint Venture
  
• LaserGen Wins Grant for Next-Gen Sequencing Test for Wound Infection Pathogens
  
• Biovest, USAMRIID Sign CRADA to Evaluate Bioreactor Platform for Antiviral Vaccines and Drugs